

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**



f3

0400 07-12  
A32436 PCT-USA-A - 072448.0309  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jacobs et al.  
Serial No.: 09/887,295 Examiner: To Be Assigned  
Filed: June 22, 2001 Group Art Unit: To Be Assigned  
For: VIRAL VECTORS HAVING ENHANCED  
EFFECTIVENESS WITH REDUCED VIRULENCE

INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with  
the United States Postal Service as first class mail in an  
envelope addressed to:  
Commissioner for Patents, Washington, D.C. 20231.

August 1, 2001

Date of Deposit

Janet M. MacLeod

Attorney Name

35,263

Registration No.

*Janet M. MacLeod*  
Signature

August 1, 2001

Date of Signature

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants, by their attorneys, hereby bring the following documents to  
the attention of the Examiner in connection with the examination of the above-captioned  
patent application:

1. U.S. Patent Application No. 09/837,998 to Jacobs et al., filed  
April 19, 2001.

2. U.S. Patent Application No. 09/837,997 to Jacobs et al., filed April 19, 2001.
3. Beattie et al., "Reversal of the Interferon-Sensitive Phenotype of a Vaccinia Virus Lacking E3L by Expression of the Reovirus S4 Gene", Journal of Virology, Vol. 69, No.1, January 1995, pp.499-505.
4. Brandt et al., "Both Carboxy- and Amino-Terminal Domains of the Vaccinia Virus Interferon Resistance Gene, E3L, Are Required for Pathogenesis in a Mouse Model", Journal of Virology, Vol. 75, No.1, January 2001, pp.850-856.
5. Chang et al., "Identification of a Conserved Motif That Is Necessary for Binding of the Vaccinia Virus E3L Gene Products to Double-Stranded RNA", Virology, Vol. 194, 1993, pp.537-547.
6. Kibler et al., "Double-Stranded RNA Is a Trigger for Apoptosis in Vaccinia Virus-Infected Cells", Journal of Virology, Vol. 71., No. 3, March 1997, pp.1992-2003.
7. Shors et al., "Complementation of Vaccinia Virus Deleted of the E3L Gene by Mutants of E3L", Virology, Vol. 239, 1997, pp.269-276.
8. U.S. Patent 6,004,777, to Tartaglia et al., issued on December 21, 1999.

Any fees necessitated by this communication may be charged to Deposit  
Account No. 02-4377. Two copies of this paper are enclosed.

Respectfully submitted,


  
Louis S. Sorell  
Patent Office Reg. No. 32,439

Marta E. Delsignore  
Patent Office Reg. No. 32,689

Janet M. MacLeod  
PTO Reg. No. 35,263

Attorneys for Applicants  
(212) 408-2597

Baker Botts LLP  
30 Rockefeller Plaza  
New York, NY 10112



<b>Form PTO-1449 U.S. Department of Commerce</b> <b>(REV. 2-82) Patent and Trademark Office</b>  <b>INFORMATION DISCLOSURE STATEMENT</b> <b>BY APPLICANT</b>  (Use several sheets if necessary)	Atty. Docket No. (A32436 PCT USA-A)	Serial No. 09/887,295
	Applicant Jacobs et al.	
	Filing Date June 22, 2001	Group To Be Assigned

### U.S. PATENT DOCUMENTS

*Exam. Init.	Document No.	Date	Name	Class	Subclass	Filing Date if Appro.
	6 0 0 4 7 7 7	12/21/99	Tartaglia et al.	435	69.1	

### FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Class	Subclass	Translation Yes No


### OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)

	U.S. Patent Application No. 09/837,998 to Jacobs et al., filed April 19, 2001.
	U.S. Patent Application No. 09/837,997 to Jacobs et al., filed April 19, 2001.
	Beattie et al., "Reversal of the Interferon-Sensitive Phenotype of a Vaccinia Virus Lacking E3L by Expression of the Reovirus S4 Gene", Journal of Virology, Vol. 69, No.1, January 1995, pp.499-505.

NY02:339453.1 Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-1449 U.S. Department of Commerce  
(REV. 2-82) Patent and Trademark Office

**INFORMATION DISCLOSURE STATEMENT  
BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.  
(A32436 PCT USA-A)

Serial No.  
09/887,295

Applicant  
Jacobs et al.

Filing Date  
June 22, 2001

Group  
To Be Assigned

		Brandt et al., "Both Carboxy- and Amino-Terminal Domains of the Vaccinia Virus Interferon Resistance Gene, E3L, Are Required for Pathogenesis in a Mouse Model", Journal of Virology, Vol. 75, No.1, January 2001, pp.850-856.
		Chang et al., "Identification of a Conserved Motif That Is Necessary for Binding of the Vaccinia Virus E3L Gene Products to Double-Stranded RNA", Virology, Vol. 194, 1993, pp.537-547.
		Kibler et al., "Double-Stranded RNA Is a Trigger for Apoptosis in Vaccinia Virus-Infected Cells", Journal of Virology, Vol. 71., No. 3, March 1997, pp.1992-2003.
		Shors et al., "Complementation of Vaccinia Virus Deleted of the E3L Gene by Mutants of E3L", Virology, Vol. 239, 1997, pp.269-276.

NY02:339453.1 Examiner

Date Considered

\* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.